NONEinactive

VITASPRING BIOMEDICAL CO. LTD.

Healthcare·Dermatology·Pre-clinical
Dermatology
2.7/10

BioSniper Score

Based on 4 of 6 signals

Market Cap

—

Cash Runway

0.3 mo

Lead Asset

x.exosome (Preclinical)

Next Catalyst

—

Tracking 2 pipeline candidates for VITASPRING BIOMEDICAL CO. LTD. · Updated within the last hour.

Go deeper on VITASPRING BIOMEDICAL CO. LTD. with Spotter

Ask follow-up questions and run a full multi-agent deep dive on NONE — live, with citations.

Ask Spotter

Score breakdownBased on 4 of 6 signals · derived from public data

Cash Runway0.1

0.3 months

Financial Health4.0

OCF $6K · Net income -$76K

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Key Financialsas of April 30, 2026

Cash

$8K

Quarterly Burn

$76K

Revenue

$0

Free Cash Flow

$6K

Total Liabilities

$4.5M

Shareholders Equity

-$4.5M

Current Ratio

0.00

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jul 2026
Today~7 mo out
Catalyst within runway

Pipeline (2 candidates)

DrugPhase
x.exosomePreclinical
x.mscPreclinical

Commercialization & Governance

Commercialization

Launch Markets
-
Commercial Strategy
We anticipate a business-to-business (B2B) model, serving institutional and clinical clients rather than direct retail customers. We intend to develop and license cell-based products, exosome formulations, and related wellness applications. We expect commercialization to occur through direct sales, distribution partnerships, or out-licensing arrangements once regulatory approvals are obtained.

Frequently asked questions

What is VITASPRING BIOMEDICAL CO. LTD.'s lead drug candidate?

VITASPRING BIOMEDICAL CO. LTD.'s most advanced tracked candidate is x.exosome (Preclinical) for Skincare, regenerative formulations, wound healing, and anti-inflammatory research.

What therapeutic areas does VITASPRING BIOMEDICAL CO. LTD. focus on?

VITASPRING BIOMEDICAL CO. LTD. develops therapies across Dermatology.

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.

Get the full picture on VITASPRING BIOMEDICAL CO. LTD.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar